PHIBRO ANIMAL HEALTH CORP-A (PAHC)
US71742Q1067 - Common Stock
Taking everything into account, PAHC scores 5 out of 10 in our fundamental rating. PAHC was compared to 198 industry peers in the Pharmaceuticals industry. Both the profitability and the financial health of PAHC get a neutral evaluation. Nothing too spectacular is happening here. PAHC has a valuation in line with the averages, but on the other hand it scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year PAHC was profitable.
In the past year PAHC had a positive cash flow from operations.
In the past 5 years PAHC has always been profitable.
Each year in the past 5 years PAHC had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of 1.52%, PAHC belongs to the top of the industry, outperforming 85.13% of the companies in the same industry.
Looking at the Return On Equity, with a value of 5.46%, PAHC belongs to the top of the industry, outperforming 88.21% of the companies in the same industry.
PAHC's Return On Invested Capital of 5.07% is amongst the best of the industry. PAHC outperforms 84.10% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for PAHC is significantly below the industry average of 16.40%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.52% | ||
| ROE | 5.46% | ||
| ROIC | 5.07% |
ROA(3y)5.03%
ROA(5y)5.38%
ROE(3y)17.7%
ROE(5y)19.26%
ROIC(3y)6.57%
ROIC(5y)7.15%
1.3 Margins
Looking at the Profit Margin, with a value of 1.50%, PAHC belongs to the top of the industry, outperforming 84.10% of the companies in the same industry.
PAHC's Profit Margin has declined in the last couple of years.
The Operating Margin of PAHC (6.33%) is better than 79.49% of its industry peers.
PAHC's Operating Margin has declined in the last couple of years.
Looking at the Gross Margin, with a value of 30.43%, PAHC is in line with its industry, outperforming 52.31% of the companies in the same industry.
PAHC's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 6.33% | ||
| PM (TTM) | 1.5% | ||
| GM | 30.43% |
OM growth 3Y-4.42%
OM growth 5Y-9.45%
PM growth 3Y-7.4%
PM growth 5Y-15.88%
GM growth 3Y-1.69%
GM growth 5Y-1.3%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so PAHC is destroying value.
PAHC has about the same amout of shares outstanding than it did 1 year ago.
PAHC has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, PAHC has a worse debt to assets ratio.
2.2 Solvency
An Altman-Z score of 2.63 indicates that PAHC is not a great score, but indicates only limited risk for bankruptcy at the moment.
The Altman-Z score of PAHC (2.63) is better than 73.33% of its industry peers.
PAHC has a debt to FCF ratio of 12.82. This is a negative value and a sign of low solvency as PAHC would need 12.82 years to pay back of all of its debts.
PAHC has a better Debt to FCF ratio (12.82) than 81.54% of its industry peers.
A Debt/Equity ratio of 1.66 is on the high side and indicates that PAHC has dependencies on debt financing.
With a Debt to Equity ratio value of 1.66, PAHC is not doing good in the industry: 78.97% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.66 | ||
| Debt/FCF | 12.82 | ||
| Altman-Z | 2.63 |
ROIC/WACC0.7
WACC7.21%
2.3 Liquidity
PAHC has a Current Ratio of 3.12. This indicates that PAHC is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 3.12, PAHC perfoms like the industry average, outperforming 48.21% of the companies in the same industry.
PAHC has a Quick Ratio of 1.60. This is a normal value and indicates that PAHC is financially healthy and should not expect problems in meeting its short term obligations.
PAHC has a Quick ratio of 1.60. This is in the lower half of the industry: PAHC underperforms 66.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.12 | ||
| Quick Ratio | 1.6 |
3. Growth
3.1 Past
PAHC shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by 0.00%.
Measured over the past years, PAHC shows a decrease in Earnings Per Share. The EPS has been decreasing by -6.85% on average per year.
PAHC shows a small growth in Revenue. In the last year, the Revenue has grown by 1.02%.
The Revenue has been growing slightly by 3.58% on average over the past years.
EPS 1Y (TTM)0%
EPS 3Y4.15%
EPS 5Y-6.85%
EPS growth Q2Q-2.94%
Revenue 1Y (TTM)1.02%
Revenue growth 3Y6.9%
Revenue growth 5Y3.58%
Revenue growth Q2Q2.18%
3.2 Future
Based on estimates for the next years, PAHC will show a small growth in Earnings Per Share. The EPS will grow by 5.14% on average per year.
The Revenue is expected to grow by 2.77% on average over the next years.
EPS Next Y-7.82%
EPS Next 2Y1.61%
EPS Next 3Y5.14%
EPS Next 5YN/A
Revenue Next Year2.03%
Revenue Next 2Y2.63%
Revenue Next 3Y2.77%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 14.70, which indicates a correct valuation of PAHC.
Based on the Price/Earnings ratio, PAHC is valued cheaply inside the industry as 88.21% of the companies are valued more expensively.
PAHC's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 24.55.
The Price/Forward Earnings ratio is 13.30, which indicates a correct valuation of PAHC.
Compared to the rest of the industry, the Price/Forward Earnings ratio of PAHC indicates a rather cheap valuation: PAHC is cheaper than 89.23% of the companies listed in the same industry.
PAHC's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 20.92.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.7 | ||
| Fwd PE | 13.3 |
4.2 Price Multiples
PAHC's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. PAHC is cheaper than 85.64% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, PAHC is valued cheaply inside the industry as 84.62% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 18.33 | ||
| EV/EBITDA | 10.15 |
4.3 Compensation for Growth
PAHC has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.61%
EPS Next 3Y5.14%
5. Dividend
5.1 Amount
PAHC has a Yearly Dividend Yield of 3.86%.
PAHC's Dividend Yield is rather good when compared to the industry average which is at 4.39. PAHC pays more dividend than 95.38% of the companies in the same industry.
Compared to an average S&P500 Dividend Yield of 2.39, PAHC pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.86% |
5.2 History
The dividend of PAHC has a limited annual growth rate of 3.70%.
PAHC has been paying a dividend for at least 10 years, so it has a reliable track record.
As PAHC did not decrease their dividend in the past 5 years, we can say the dividend looks stable.
Dividend Growth(5Y)3.7%
Div Incr Years0
Div Non Decr Years9
5.3 Sustainability
131.59% of the earnings are spent on dividend by PAHC. This is not a sustainable payout ratio.
The dividend of PAHC is growing, but earnings are growing more, so the dividend growth is sustainable.
DP131.59%
EPS Next 2Y1.61%
EPS Next 3Y5.14%
PHIBRO ANIMAL HEALTH CORP-A
NASDAQ:PAHC (5/2/2024, 3:30:02 PM)
After market: 16.76 0 (0%)16.76
+0.41 (+2.51%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap678.78M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.86% |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.7 | ||
| Fwd PE | 13.3 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.52% | ||
| ROE | 5.46% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 6.33% | ||
| PM (TTM) | 1.5% | ||
| GM | 30.43% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover1.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.66 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.12 | ||
| Quick Ratio | 1.6 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)0%
EPS 3Y4.15%
EPS 5Y
EPS growth Q2Q
EPS Next Y-7.82%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)1.02%
Revenue growth 3Y6.9%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y